Team: International led by the Ontario Cancer Institute
Journal: Cancer Cell (13 / 04 U.S.)
BCL-6 protein was identified as the source of over half of non-Hodgkin lymphoma, and many forms of diffuse large B cell lymphoma
We know that blocking this protein, BCL-6 by knockout experience for example, kills tumor cells of diffuse large B cell lymphomas This protein was therefore an attractive therapeutic target. However, as a transcription factor, it acts through protein-protein interaction, lockable hard by a small molecule.
However, after its three-dimensional structure elucidated by crystallography 3D, the researchers carried out a docking of the molecule with more than a million compound (virtual simulation of the interaction between the molecule and the compound) and were able to discover 79-6.
Tested on mice bearing human lymphoma cells, 79-6 decreased very significantly the tumor cells with low toxicity. It is therefore an attractive therapeutic compound.
http://www.bulletins-electroniques.com/actualites/63082.htm
0 comments:
Post a Comment